loading page

Inhibition of interleukin 6 signalling and renal function: a Mendelian randomization study
  • +1
  • David Ryan,
  • Ville Karhunen,
  • Drew Walker,
  • Dipender Gill
David Ryan
St George's University Hospitals NHS Foundation Trust
Author Profile
Ville Karhunen
Imperial College London
Author Profile
Drew Walker
St George's University Hospitals NHS Foundation Trust
Author Profile
Dipender Gill
St George's University Hospitals NHS Foundation Trust
Author Profile

Abstract

Inhibition of interleukin 6 (IL-6) signalling has been proposed as a potential cardioprotective strategy for patients with chronic kidney disease (CKD) but the direct renal effects of IL-6 inhibition are not established. A Mendelian randomization (MR) study was performed to investigate the association of genetically proxied inhibition of IL-6 signalling with estimated glomerular filtration rate (eGFR), CKD and blood urea nitrogen (BUN). Inverse variance weighted MR was used as the main analysis, with sensitivity analyses performed using simple median, weighted median and MR-Egger methods. There was no evidence for an association of genetically proxied inhibition of IL-6 signalling (scaled per unit decrease in natural log transformed C-reactive protein) with log eGFR (0.002, 95% confidence interval -0.004 – 0.008), BUN (0.088, 95% confidence interval -0.003 – 0.019) and CKD (odds ratio 1.018, 95% confidence interval 0.899 – 1.153). These findings suggest that inhibition of IL-6 signalling is unlikely to have a direct effect on renal function.

Peer review status:Published

07 Oct 2020Submitted to British Journal of Clinical Pharmacology
08 Oct 2020Submission Checks Completed
08 Oct 2020Assigned to Editor
13 Oct 2020Reviewer(s) Assigned
20 Nov 2020Review(s) Completed, Editorial Evaluation Pending
30 Nov 2020Editorial Decision: Revise Major
14 Dec 20201st Revision Received
15 Dec 2020Submission Checks Completed
15 Dec 2020Assigned to Editor
15 Dec 2020Review(s) Completed, Editorial Evaluation Pending
23 Dec 2020Editorial Decision: Accept
04 Jan 2021Published in British Journal of Clinical Pharmacology. 10.1111/bcp.14725